自闭症频谱(ASD) 治疗市场规模、份额和成长分析：按药物治疗、疾病、通路和地区划分 - 产业预测，2024-2031 年

Autism Spectrum Disorder Therapeutics Market Size, Share, Growth Analysis, By Drug Therapy, By Disease, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月12日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022 年全球自闭症频谱(ASD) 治疗市场规模为 19.2 亿美元，在预测期内从 2023 年的 20.7 亿美元增长到 2031 年的 37.7 亿美元（预计 2022 年复合年增长率为 7.80%） 2024 -2031）。

在意识提高、早期诊断能力以及研发进步的推动下，全球泛自闭症障碍(ASD) 治疗市场正处于强劲成长轨道。针对自闭症谱系障碍核心症状（例如沟通和社交互动方面的挑战）的有效治疗的需求不断增长。此外，政府对自闭症谱系障碍研究的支持，以及不断努力创造个人化和创新的治疗方法，正在进一步推动市场扩张。儘管出现这种成长，自闭症谱系障碍治疗的竞争格局仍然很激烈，製药公司努力为全球自闭症患者推出创新和更有效的治疗解决方案。值得注意的是，美国ASD 治疗市场预计在接下来的预测期内将保持健康的复合年增长率，突显了该行业的乐观前景。随着公司继续采取创新和复杂的方法来满足患者不断变化的需求，相关人员可以预见未来几年充满活力且日益多样化的市场格局。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Curemark, LLC（US）
Alembic Pharmaceuticals Limited（India）
Yamo Pharmaceuticals（US）
PaxMedica（US）
F. Hoffmann-La Roche Ltd（Switzerland）
Aurobindo Pharma Ltd.（India）
Otsuka Holdings Co. Ltd.（Japan）
Janssen Pharmaceuticals, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
H. Lundbeck A/S（Denmark）
AbbVie Inc.（US）
Eli Lilly and Company（US）
Pfizer Inc.（US）
Novartis International AG（Switzerland）
Neurocrine Biosciences, Inc.（US）
Acadia Pharmaceuticals Inc.（US）
Intra-Cellular Therapies, Inc.（US）
Amedisys, Inc.（US）
Sage Therapeutics, Inc.（US）
Purdue Pharma LP（US）
Horizon Therapeutics plc（Ireland）
Karuna Therapeutics, Inc.（US）

简介目录

Product Code: SQMIG35I2192

Global Autism Spectrum Disorder Therapeutics Market size was valued at USD 1.92 billion in 2022 and is poised to grow from USD 2.07 billion in 2023 to USD 3.77 billion by 2031, growing at a CAGR of 7.80% during the forecast period (2024-2031).

The global autism spectrum disorder (ASD) therapeutics market is on a robust growth trajectory, fueled by heightened awareness, early diagnosis capabilities, and advancements in research and development. The demand for effective treatments that specifically address the core symptoms of ASD, including challenges in communication and social interactions, is on the rise. Additionally, ongoing initiatives to create personalized and innovative therapies, complemented by government support for ASD research, are further propelling market expansion. Despite this growth, the ASD therapeutics landscape remains intensely competitive, with pharmaceutical companies striving to introduce groundbreaking and more efficient therapeutic solutions for individuals with autism on a global scale. Notably, the US ASD therapeutics market is projected to sustain a healthy compound annual growth rate (CAGR) throughout the upcoming forecast period, underscoring the optimistic outlook for the sector. As companies continue to innovate and refine their approaches in response to the evolving needs of patients, stakeholders can anticipate a dynamic and increasingly diversified market landscape in the years to come.

Top-down and bottom-up approaches were used to estimate and validate the size of the global autism spectrum disorder therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global autism spectrum disorder therapeutics Market Segmental Analysis

Global Autism Spectrum Disorder Therapeutics Market is segmented by Drug Therapy, Disease, Distribution Channel, and region. Based on Drug Therapy, the market is segmented into Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Sleep Medications, and Others. Based on Disease, the market is segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder (PDD), and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the global autism spectrum disorder therapeutics Market

The escalating prevalence of autism spectrum disorder (ASD) worldwide is a critical driver propelling the growth of the global ASD therapeutics market. Current statistics from the World Health Organization reveal that approximately 1 in 160 children is diagnosed with ASD, fostering an urgent need for effective therapeutic interventions. This rise in diagnosis has consequently increased awareness and facilitated earlier detection of ASD, compelling healthcare providers and policymakers to prioritize the development of targeted therapies. The sustained drive towards innovative research and development is anticipated to yield a wave of novel treatments, thereby addressing the significant unmet needs within the ASD patient population and expanding market opportunities.

Restraints in the global autism spectrum disorder therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market faces significant restraints primarily due to the intrinsic complexity of ASD. This heterogeneous condition exhibits a broad spectrum of symptoms and varying responses to treatments among individuals, complicating the establishment of standardized therapeutic approaches. Furthermore, the unclear etiology and underlying mechanisms of ASD impede efficient drug development, leading to challenges in creating targeted interventions. This variability results in slower drug approval processes, along with potential limitations in the effectiveness of available therapies. Consequently, the multifaceted nature of ASD underscores the difficulties in advancing therapeutics in this market.

Market Trends of the global autism spectrum disorder therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market is witnessing significant trends that reflect innovations and shifting approaches in treatment modalities. There is a heightened focus on early intervention strategies and personalized therapies informed by genetic insights, aiming to provide tailored solutions for individuals with ASD. Furthermore, robust investments in research and development are paving the way for novel treatment options. The integration of technology, particularly in behavioral interventions and remote monitoring, is enhancing accessibility to care, thereby broadening the outreach to affected families. Increased awareness and advocacy are further accelerating the demand for effective treatments, prompting pharmaceutical companies to intensify their efforts in this crucial therapeutic landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Autism Spectrum Disorder Therapeutics Market by Drug Therapy

Market Overview
Antipsychotic Drugs
SSRIs/Antidepressants
Stimulants
Sleep Medications
Others

Autism Spectrum Disorder Therapeutics Market by Disease

Market Overview
Autistic Disorder
Asperger Syndrome
Pervasive Developmental Disorder (PDD)
Others

Autism Spectrum Disorder Therapeutics Market by Age Group

Market Overview
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

Autism Spectrum Disorder Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Curemark, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alembic Pharmaceuticals Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yamo Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PaxMedica (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Holdings Co. Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurocrine Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intra-Cellular Therapies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amedisys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sage Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Purdue Pharma L.P. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karuna Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments